Binimetinib Disease Interactions
There are 3 disease interactions with binimetinib.
Binimetinib (applies to binimetinib) cardiomyopathy
Moderate Potential Hazard, Moderate plausibility.
Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with binimetinib in combination with encorafenib. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving treatment was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of the patients. Ejection fraction should be assessed by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment. The safety of this therapy has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with binimetinib.
Binimetinib (applies to binimetinib) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Binimetinib concentrations may increase in patients with moderate or severe hepatic impairment. Reduce the dose of binimetinib for patients with moderate (total bilirubin > 1.5 and = 3 × ULN and any AST) or severe (total bilirubin levels > 3 × ULN and any AST) hepatic impairment. Dose adjustment is not recommended in patients with mild hepatic impairment (total bilirubin > 1 and = 1.5 × ULN and any AST or total bilirubin = ULN and AST > ULN).
Binimetinib (applies to binimetinib) retinal disturbances
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Retinal Disorder, Glaucoma/Intraocular Hypertension
Retinal vein occlusion (RVO) is a known class- related adverse reaction of MEK inhibitors and may occur in patients treated with binimetinib in combination with encorafenib. The safety of binimetinib has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes. An ophthalmologic evaluation should be performed for patient reporting acute vision loss or other visual disturbance within 24 hours. Treatment should be discontinued in patients with documented RVO.
Binimetinib drug interactions
There are 171 drug interactions with binimetinib.
More about binimetinib
- binimetinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.